News
| 7 min read
Men have long lacked reversible contraceptives, but new hormonal and non-hormonal methods in development could finally give them control over family planning.
| 3 min read
A novel eye drop from LENZ Therapeutics represents the first time the FDA has approved aceclidine, a cholinergic agonist, in any drug.
| 3 min read
The kidney structures replicate newborn-level maturity, enabling studies of complex disease features such as fibrosis and drug toxicity.
| 3 min read
From multiomic diagnostics to quantum computing, leading experts share the untapped opportunities that could reshape the future of therapeutics.
| 4 min read
A gene therapy trial halted after a child’s death, a CRISPR test to detect tuberculosis, a new device for antisense therapies, and more led the news this week.
| 2 min read
A new class of small-molecule drugs could represent a therapeutic modality aimed at eliminating disease-causing proteins before they spread in the body.
| 4 min read
Trontinemab clears amyloid faster and more safely than previous drugs for Alzheimer’s disease. Will it convince skeptical regulators?
| 3 min read
The drugmaker expands access to AI-driven discovery, but also positions its technology to become a standard across the sector.
| 3 min read
New research suggests an unexpected role for T cells during a tumor’s evolution from benign to malignant.
| 4 min read
New results from an anti-seizure medication and blood cancer drug, a new AI platform, and a novel heart disease drug led drug discovery this week.
| 2 min read
A disease once synonymous with a shortened lifespan is now a model for how drug discovery can directly alter the natural history of genetic disorders.
| 5 min read
Computational models are reshaping how therapies are discovered, tested, and optimized.
